By Stephen NakrosisShares of Larimar Therapeutics were trading higher in after-hours action Monday, following news the U.S. Food and Drug Administration has lifted a partial clinical hold on the nomlabofusp program in Friedreich's Ataxia, an inherited disorder of the nervous system. The partial clinical hold was removed following a review of data from a recently completed four-week, placebo-controlled Phase 2 dose exploration study, which included data from both 25 mg and 50 mg cohorts. In addition, 3 patients had levels above 50% of the average healthy volunteer level. Interim data from an ongoing open label extension study is expected in the fourth quarter of this year, the company said. Write to Stephen Nakrosis at stephen.nakrosis@wsj.com(END) Dow Jones NewswiresMay 20, 2024 17:10 ET (21:10 GMT)Copyright (c) 2024 Dow Jones & Company, Inc.

Source: Wall Street Journal May 21, 2024 03:16 UTC